Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI0562) Administered Prior to Surgical Resection in Patients With Head and Neck Squamous Cell Carcinoma or Melanoma
Status: Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2019
Price : $35 *
At a glance
- Drugs Tavolimab (Primary)
- Indications Head and neck cancer; Malignant melanoma; Squamous cell cancer
- Focus Pharmacodynamics
- 31 Jul 2018 Planned End Date changed from 1 Dec 2026 to 1 Dec 2024.
- 31 Jul 2018 Planned primary completion date changed from 1 Dec 2024 to 1 Jul 2022.
- 03 Apr 2018 Planned initiation date changed from 1 Feb 2018 to 1 Jul 2018.